Previous close | 10.10 |
Open | N/A |
Bid | 20.50 |
Ask | 24.50 |
Strike | 95.00 |
Expiry date | 2024-08-16 |
Day's range | 10.10 - 10.10 |
Contract range | N/A |
Volume | |
Open interest | 1 |
Bristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer.
Roche (RHHBY) gets exclusive, target-specific rights to Ascidian's RNA exon editing technology for undisclosed neurological targets for an initial payment of $42 million.
Terns Pharmaceuticals, Inc. (TERN) outperforms the industry year to date on encouraging pipeline progress of its oncology candidate.